Assessing Health and Economic Benefits of Omega-3 Fatty Acid Supplementation on Cardiovascular Disease in the Republic of Korea

Overview

Journal Healthcare (Basel)

Specialty Health Services

Date 2023 Aug 26

PMID 37628562

Authors

Moon Seong Kim

Jin Man Kim

Sang Gyeong Lee

Eun Jin Jung

Sang Hoon Lee

Wen Yan Huang

Bok Kyung Han

Da Eun Jung

Sung Bum Yang

Inbae Ji

Young Jun Kim

Ji Youn Hong

Affiliations

Soon will be listed here.

Abstract

Background: Cardiovascular disease (CVD) is the primary cause of mortality worldwide and imposes a significant social burden on many countries.

Methods: This study assessed the health and economic benefits of omega-3 associated with CVD. The meta-analysis estimated the risk ratio (RR) and absolute risk reduction (ARR), and the economic impact was calculated using direct and indirect costs related to CVD treatments in Korean adults.

Results: A total of 33 studies were included in the meta-analysis on CVD outcomes, with 80,426 participants in the intervention group and 80,251 participants in the control group. The meta-analysis determined a significant reduction in omega-3 in CVD (RR = 0.92, 95% CI: 0.86~0.97) and ARR (1.48%). Additionally, the subgroup analysis indicated that higher doses and the long-term consumption of omega-3 could further enhance these effects. After applying ARR from meta-analysis to the target population of about 1,167,370 in 2021, the Republic of Korea, it was estimated that omega-3 consumption could result in an economic benefit of KRW 300 billion by subtracting the purchase expenses of omega-3 supplements from the total social cost savings.

Conclusion: Omega-3 supplements can help to reduce the risk of CVD and subsequent economic benefits in the Republic of Korea.

References

Rice H, Bernasconi A, Maki K, Harris W, von Schacky C, Calder P . Conducting omega-3 clinical trials with cardiovascular outcomes: Proceedings of a workshop held at ISSFAL 2014. Prostaglandins Leukot Essent Fatty Acids. 2016; 107:30-42. DOI: 10.1016/j.plefa.2016.01.003. View

Maki K, Palacios O, Bell M, Toth P . Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps. J Clin Lipidol. 2017; 11(5):1152-1160.e2. DOI: 10.1016/j.jacl.2017.07.010. View

Manson J, Cook N, Lee I, Christen W, Bassuk S, Mora S . Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med. 2018; 380(1):23-32. PMC: 6392053. DOI: 10.1056/NEJMoa1811403. View

Rizos E, Ntzani E, Bika E, Kostapanos M, Elisaf M . Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012; 308(10):1024-33. DOI: 10.1001/2012.jama.11374. View

Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S . Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J. 2009; 73(7):1283-90. DOI: 10.1253/circj.cj-08-1197. View

Einvik G, Klemsdal T, Sandvik L, Hjerkinn E . A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk. Eur J Cardiovasc Prev Rehabil. 2010; 17(5):588-92. DOI: 10.1097/HJR.0b013e328339cc70. View

Siscovick D, Barringer T, Fretts A, Wu J, Lichtenstein A, Costello R . Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association. Circulation. 2017; 135(15):e867-e884. PMC: 6903779. DOI: 10.1161/CIR.0000000000000482. View

Grundt H, Nilsen D, Hetland O, Mansoor M . Clinical outcome and atherothrombogenic risk profile after prolonged wash-out following long-term treatment with high doses of n-3 PUFAs in patients with an acute myocardial infarction. Clin Nutr. 2004; 23(4):491-500. DOI: 10.1016/j.clnu.2003.09.005. View

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View

10.

Raitt M, Connor W, Morris C, Kron J, Halperin B, Chugh S . Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA. 2005; 293(23):2884-91. DOI: 10.1001/jama.293.23.2884. View

11.

Sanyal A, Abdelmalek M, Suzuki A, Cummings O, Chojkier M . No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology. 2014; 147(2):377-84.e1. DOI: 10.1053/j.gastro.2014.04.046. View

12.

Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H . OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010; 122(21):2152-9. DOI: 10.1161/CIRCULATIONAHA.110.948562. View

13.

Newcombe R, Bender R . Implementing GRADE: calculating the risk difference from the baseline risk and the relative risk. Evid Based Med. 2013; 19(1):6-8. PMC: 3913115. DOI: 10.1136/eb-2013-101340. View

14.

Selvaraj S, Bhatt D, Steg P, Miller M, Brinton E, Jacobson T . Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT. J Am Heart Assoc. 2022; 11(7):e024999. PMC: 9075460. DOI: 10.1161/JAHA.121.024999. View

15.

Gaba P, Bhatt D, Steg P, Miller M, Brinton E, Jacobson T . Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. J Am Coll Cardiol. 2022; 79(17):1660-1671. DOI: 10.1016/j.jacc.2022.02.035. View

16.

Hu Y, Hu F, Manson J . Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants. J Am Heart Assoc. 2019; 8(19):e013543. PMC: 6806028. DOI: 10.1161/JAHA.119.013543. View

17.

Hwang J, Kim W, Jeong S, Kwon O . Evidence-based estimation of health care cost savings from the use of omega-3 supplementation among the elderly in Korea. Nutr Res Pract. 2015; 9(4):400-3. PMC: 4523484. DOI: 10.4162/nrp.2015.9.4.400. View

18.

Shi J, Luo D, Weng H, Zeng X, Lin L, Chu H . Optimally estimating the sample standard deviation from the five-number summary. Res Synth Methods. 2020; 11(5):641-654. DOI: 10.1002/jrsm.1429. View

19.

Roncaglioni M, Tombesi M, Avanzini F, Barlera S, Caimi V, Longoni P . n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013; 368(19):1800-8. DOI: 10.1056/NEJMoa1205409. View

20.

Nosaka K, Miyoshi T, Iwamoto M, Kajiya M, Okawa K, Tsukuda S . Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study. Int J Cardiol. 2016; 228:173-179. DOI: 10.1016/j.ijcard.2016.11.105. View